IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4435
Positioning
Market Dominance
Manufacturing
Medical Equipment
$3M
Jennifer Ernst
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, a medical device intended to relieve sinus and nasal inflammation.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$TIVC Tivic Health Systems, Inc. | 31 | 15 | 22 | 40 | - | - | -133.4% | -119.8% | 17.5% | -1809.2% | -1826.2% | 4.3% | 0.0% | 11.0x | $3M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Tivic Health Systems, Inc. (TIVC) receives a "Avoid" rating with a composite score of 31.3/100. It ranks #4435 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for TIVC.
View All RatingsROE proxy -133.4% (sector -1.9%)
GM 17% vs sector 44%, OM -1809% vs sector 3%
Capital turnover N/A, R&D intensity 611.9%
Rev growth 4%, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Tivic Health Systems, Inc. (TIVC) as Avoid with a composite score of 31.3/100 at a current price of $0.75. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Tivic Health Systems, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 31.3/100 places it at rank #4435 in our full universe.
No Moat
Very High
Poor
Fair Value
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Tivic Health Systems, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Tivic Health Systems, Inc. with an Avoid rating, assigning a composite score of 31.3/100 and 1 out of 5 stars. Ranked #4435 of 7,333 stocks, TIVC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Tivic Health Systems, Inc. registers a weak quality score of just 15/100, indicating significant profitability challenges. The company reports a return on equity of -133.4% (sector avg: -1.9%), gross margins of 17.5% (sector avg: 44.1%), net margins of -1826.2% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
TIVC registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.34x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Tivic Health Systems, Inc.'s investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 4.3% vs. a sector average of 6.7% and a return on assets of -119.8% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
TIVC is currently showing below-average momentum at 40/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 4.3% year-over-year, while a beta of 3.92 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
Tivic Health Systems, Inc. registers a low stability score of 9/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 3.92 and a debt-to-equity ratio of 11.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
TIVC's short interest factor score of 83/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include high market sensitivity (beta: 3.92), elevated leverage (D/E: 11.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $3M, Tivic Health Systems, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Tivic Health Systems, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4435 of 7,333 overall (40th percentile). Key comparisons include ROE of -133.4% trailing the -1.9% sector median and operating margins of -1809.2% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While TIVC currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (9) would have the largest impact on the composite score.
ROE 6923% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 60% BELOW SECTOR MEDIAN
Op. Margin 72178% BELOW SECTOR MEDIAN
Initial presentation on January 26, 2026 showcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (Nasdaq:TIVC), ...
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share. Westport Fuel Systems shares dipped 9.9% to $6.52 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Stoke Therapeutics, Inc. (NASDAQ: STOK) shares gained 72.6% to $11.24 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. C3is Inc. (NASDAQ: CISS) climbed 65% to $0.0581 after the company reported a year-over-year increase in fourth-quarter financial results. OpGen, Inc. (NASDAQ: OPGN) shares climbed 48.2% to $0.7039 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million. Mesoblast Limited (NASDAQ: MESO) gained 43.2% to $3.1501. Mesoblast was notified by the U.S. FDA that available clinical data from Phase 3 trial appear sufficient to support BLA submission for Remestemcel-L in children with steroid-refractory acute graft versus host disease. Praxis Precision Medicines Inc (NASDAQ: PRAX) gained 31.9% to $66.63 after the company reported results from a Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. Nuvation Bio Inc (NYSE: NUVB) climbed 24.4% to $2.80 after BTIG upgraded the stock from Neutral to Buy. Check-Cap Ltd. (NASDAQ: CHEK) shares gained 24.3% to $2.40 after the company announced that it entered into a definitive Business Combination Agreement with Nobul AI. Viking Therapeutics ...
Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Stoke Therapeutics shares jumped 69.7% to $11.03 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Check-Cap Ltd. (NASDAQ: CHEK) shares gained 38.3% to $2.67 in pre-market trading. Nobul AI Corp entered into business combination agreement with Check-Cap. C3is Inc. (NASDAQ: CISS) rose 35.2% to $0.0476 in pre-market trading. C3is is expected to release its fourth quarter financial results before the opening bell on March 26, 2024. OpGen, Inc. (NASDAQ: OPGN) gained 30.4% to $0.6196 in pre-market trading after the company announced David Lazar will invest $3 million in preferred stock and take over as CEO. Mesoblast Limited (NASDAQ: MESO) gained 23.2% to $2.71 in pre-market trading. Mesoblast was notified by the U.S. FDA that available clinical data from Phase 3 trial appear sufficient to support BLA submission for Remestemcel-L in children with steroid-refractory ...
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales guidance below estimates. UPS reported a fourth-quarter fiscal 2023 revenue decline of 7.8% year-over-year to $24.92 billion, missing the consensus of $25.43 billion. Adjusted EPS was $2.47, down from $3.62 in Q4 2022, in line with the consensus. United Parcel Service shares dipped 8.3% to $145.04 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Agape ATP Corporation (NASDAQ: ATPC) shares jumped 79% to $0.9120. Pixelworks, Inc. (NASDAQ: PXLW) rose 56.8% to $2.3209 after the company entered into a multi-year agreement with Walt Disney Studios. Agrify Corporation (NASDAQ: AGFY) surged 50.7% to $0.9120 after a 13D filing showed I-Tseng Jenny Chan reported a 49.99% stake in the company. Rail Vision Ltd. (NASDAQ: RVSN) gained 38.8% to $20.38 after the company announced its next generation AI-based computer to be incorporated in its Main Line and Switch Yard systems. Inspire Veterinary Partners, Inc. (NASDAQ: IVP) climbed 38% to $0.2359 after falling around 24% on Monday. Inspire Veterinary Partners recently filed a prospectus related to up to a $5 million public offering. Sanmina Corporation (NASDAQ: SANM) shares climbed 36.7% to $69.21 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Selina Hospitality PLC (NASDAQ: SLNA) gained 20.8% to $0.4603. C3is Inc. (NASDAQ: CISS) shares surged 19.1% to $0.1609 after a 13G filing showed S.H.N. Financial reported a 9.1% stake in the company. Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) rose 18.2% to $0.39. Kura Oncology, Inc. (NASDAQ: KURA) climbed 16.1% to $21.60. Kura Oncology reported preliminary ziftomenib combination data in acute myeloid leukemia. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 13.9% to $1.56 after gaining more than 25% on ...
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company’s quarterly sales came in at $8.37 million versus estimates of $8.75 million. Shapeways shares fell 20.8% to $2.36 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) shares climbed 62.4% to $2.16 after the company reported third-quarter results. Chemomab Therapeutics Ltd. (NASDAQ: CMMB) shares jumped 55% to $0.9497 after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease. Heron Therapeutics, Inc. (NASDAQ: HRTX) climbed 50.8% to $0.8143 after the company reported mixed third-quarter financial results and issued guidance. Kinnate Biopharma Inc. (NASDAQ: KNTE) rose 47.7% to $2.32. The company’s board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company. SciSparc Ltd. (NASDAQ: SPRC) gained 44.5% to $6.30. SciSparc said 'trial results indicated that SciSparc's proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.' Evelo Biosciences, Inc. (NASDAQ: EVLO) gained 36% to $0.47. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) climbed 34.3% to $1.75. Solid Biosciences Inc. (NASDAQ: SLDB) shares rose 32.7% to $2.83. Solid Biosciences announced IND clearance by the FDA for duchenne muscular dystrophy gene therapy candidate SGT-003. MGO Global, Inc. (NASDAQ: MGOL) shares climbed 32.4% to $0.6566 after reporting a sharp rise in third-quarter sales. Beyond Air, Inc. (NASDAQ: XAIR) gained 28% to $1.7920. AST SpaceMobile, Inc. (NASDAQ: ASTS) rose 28% to $4.8262 following third-quarter results. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 25.2% to $24.34 after the company reported a ...
Above 50MA
37.18%
Net New Highs
+51081